Nexmos and Daewoong Pet Begin Joint Clinical Development of 'Companion Dog Dementia Treatment'

[Asia Economy Reporter Jo In-kyung] Bio company Nexmos has announced on the 14th that it has signed a strategic partnership agreement with Daewoong Pet, which develops veterinary pharmaceuticals and operates a pet healthcare business, for joint research and product development of pet therapeutics.

Through this agreement, Nexmos and Daewoong Pet will officially proceed with joint clinical development to verify the efficacy and safety of 'NXP031,' a DNA aptamer complex that has shown antioxidant and cognitive improvement effects, for canine dementia (Cognitive Dysfunction Syndrome, CDS).

Canine CDS exhibits symptoms similar to human Alzheimer's dementia, such as barking without reason in the middle of the night or frequent urination and defecation accidents. According to UC DAVIS in California, USA, 14% of dogs aged 8 and older suffer from CDS, also known as canine dementia, with 28% of dogs aged 12-13 and 68% of dogs aged 16-17 showing CDS symptoms.

The two companies expect that if this new drug development succeeds, there will be various cases demonstrating the therapeutic effects on pet dementia. They believe that if NXP031, which reduces the causative substances of dementia, proves to be highly effective in treating canine dementia, the likelihood of success as a new drug for Alzheimer's dementia will be high.

Shim Jeong-wook, CEO of Nexmos, explained, "Most drug developments proceed with clinical trials on humans after animal model trials using mice, but conducting clinical trials on dogs before humans has the advantage of predicting the likelihood of success as a therapeutic and reducing the cost and time of clinical trials."

Moon Jae-bong, CEO of Daewoong Pet, said, "We expect to contribute to extending the healthy lifespan of dogs and promoting healthy companionship between owners and their pets through Nexmos' diverse research pipelines," adding, "We will do our best to launch therapeutics that care for canine dementia and immunity."

Nexmos is the first in the world to develop Aptamin, a core material that maximizes the stability and efficacy of antioxidants by delaying or inhibiting oxidation through DNA aptamers, and holds the original technology. Nexmos and Daewoong Pet plan to promote the development of various therapeutics using Nexmos' new substances not only for dementia but also for pneumonia and other conditions.

This content was produced with the assistance of AI translation services.